🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Consuming alcohol while taking Olmesan 20 may result in an increased and excessive feeling of drowsiness.
While using Olmesan 20 during pregnancy, there is a clear evidence of potential risk to the developing fetus, making it unsafe to use. However, in rare life-threatening situations where the benefits of the medication outweigh the potential risks, a doctor may prescribe it. It is important to consult a doctor for advice on the use of this medication during pregnancy.
There is a high likelihood that using Olmesan 20 during breastfeeding may be unsafe. Although there is limited data in humans, it suggests that the medication may enter the breast milk and cause harm to the baby.
If you experience symptoms such as decreased alertness, changes in vision, drowsiness, or dizziness while taking Olmesan 20, it may impair your ability to drive. Therefore, it is advised to avoid driving or operating machinery until these symptoms subside.
Olmesan 20 should be used with caution in patients with kidney disease.
Olmesan 20 should be used with caution in patients with liver disease.
Used in adults, children, and adolescents (aged 6 to 18 years):
Common or very common:
Uncommon: Angina, rash, dizziness.
Very rare: Headache, myalgia, itching, thrombocytopenia, urticaria.
It relaxes the blood vessel by blocking the action of a chemical that usually makes blood vessels tighter. This lowers the blood pressure, allowing the blood to flow more smoothly to different organs and the heart to pump more efficiently.
Olmesartan is suitable for the treatment of mild to moderate essential hypertension. Olmesartan can be used alone or in combination with the diuretic thiazide.
Olmesan 20 is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. Regardless of the source or route of synthesis of angiotensin II, it is expected to block all the effects of angiotensin II-mediated by AT1 receptors. Selective antagonism of the angiotensin II receptor (AT1) leads to an increase in plasma renin levels and angiotensin I and II concentrations, as well as a decrease in the plasma concentration of aldosterone. Angiotensin II is the main vasoactive hormone of the renin-angiotensin-aldosterone system (RAAS), which plays an important role in the pathophysiology of hypertension through type 1 (AT1) receptors.
Adults: the dosage must be individualized. The usual starting dose is 10 mg once a day. For patients whose blood pressure is not adequately controlled with the dose, the dose can be increased to 20 mg, once daily as the optimal dose. For patients who need to lower their blood pressure further after 2 weeks of treatment, the olmesartan dose can be increased to 40 mg. Doses greater than 40 mg do not appear to have a greater effect.
Pediatric Use: Safety and efficacy in pediatric patients have not been established.
Use in the elderly: Of the total number of hypertensive patients who received Olmesan 20 in clinical studies, more than 20% were 65 years and years or older, and more than 5% were 75 years or older. No overall difference in efficacy or safety was observed between the elderly patient and the younger patients.
In healthy volunteers, no significant drug interactions were reported in the study of olmesartan medoxomil combined with digoxin or warfarin. The bioavailability of Olmesartan was not significantly changed by the co-administration of antacids [Al (OH) 3 / Mg (OH) 2]. Olmesartan
Medoxomil is not metabolized by the cytochrome P450 system and has no effect on P450 enzymes; therefore, it is not expected to interact with drugs that inhibit, induce, or be metabolized by these enzymes.
Olmesartan is contraindicated in patients who are allergic to any component of this product.
Pregnancy category C (early pregnancy) and D (second and third trimester)
Fetal / Neonatal Morbidity and Mortality: Drugs that act directly on the renin-angiotensin system can cause morbidity and death in pregnant women and newborns. angiotensin. When pregnancy is detected, Olmesan 20 should be stopped as soon as possible.
Patients with low blood volume or saline insufficiency: In patients with the activated renin-angiotensin system, such as patients with blood volume and/or saline insufficiency (for example, patients receiving high-dose diuretics), start using omega. treatment with Medoxomil Tan. Treatment should be started under close medical supervision. If hypotension occurs, the patient should be placed supine and an intravenous infusion of normal saline should be given if necessary.
Keep out of the reach of children. Store the original packaging in a cool, dry place. Avoid light and avoid humidity.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.